Topotecan治療子宮頸癌的檢視

Chemotherapy for Advanced Cervical Cancer with Topotecan

子宮頸癌雖是最能預防的一種癌症，但仍是台灣最多的婦科癌症，且晚期或復發性的子宮頸癌預後仍差，5年生存率僅10-20％。因此，除加強預防外，如何延長這些晚期患者的生存率，及改善其生活品質十分重要。2006年，美國食品藥物管理局（Food and Drug Administration，FDA）已通過合併使用topotecan和cisplatin，來治療已無法以手術或放射線治癒的復發或持續性的子宮頸癌。現階段治療復發性的子宮頸癌除手術外，仍以cisplatin為主要被接受的化學治療藥物，topotecan也證明對晚期的子宮頸癌十分有效。Topotecan加上cisplatin作為放射線的同步治療，也是研究的方向。

In Taiwan, cervical cancer is the most common cancer in women. The 5-year overall survival rate for advanced or relapsed cervical cancer is poor ranging from 10 to 20%. Recently, topotecan has shown promise in a number of clinical trials in cervical patients. Cisplatin monotherapy had been the gold standard chemotherapy for advanced cervical carcinoma. In several trials, the combination of cisplatin and topotecan demonstrated higher efficacy in terms of response rate, disease-free survival and overall survival. Topotecan plus cisplatin combination regimen was approved by the Food and Drug Administration(FDA) in 2006, for use in recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery or radiation therapy. Furthermore, the addition of topotecan to cisplatin during pelvic radiation for locally advanced cervical cancer appears promising result.